Back to top
more

Accuray (ARAY)

(Real Time Quote from BATS)

$1.28 USD

1.28
226,572

0.00 (0.00%)

Updated Aug 4, 2025 11:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions

by Zacks Equity Research

Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.

Zacks Equity Research

DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook

by Zacks Equity Research

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.

Zacks Equity Research

TEM Stock Declines Following Preliminary Q4 Sales Miss

by Zacks Equity Research

Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.

Zacks Equity Research

PacBio Stock May Gain Following the Collaborated Launch of GutID

by Zacks Equity Research

PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.

Zacks Equity Research

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

by Zacks Equity Research

DXCM continues to raise optimism among investors owing to its strong product portfolio.

Zacks Equity Research

Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?

by Zacks Equity Research

Here is how Aptevo Therapeutics Inc. (APVO) and Accuray (ARAY) have performed compared to their sector so far this year.

Zacks Equity Research

PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics

by Zacks Equity Research

PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.

Zacks Equity Research

Tempus AI Stock Falls Despite Collaboration Announcement With Genialis

by Zacks Equity Research

TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.

Zacks Equity Research

Here's Why You Should Add Accuray Stock to Your Portfolio Now

by Zacks Equity Research

ARAY's solid product demand and revenue growth raise optimism about the stock.

Zacks Equity Research

BDSX Stock Rises After Publication of Study Data for Nodify CDT Test

by Zacks Equity Research

Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.

Zacks Equity Research

Stryker Stock Falls Despite the Agreement to Acquire Inari Medical

by Zacks Equity Research

SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.

Zacks Equity Research

Here's Why You Should Retain BDX Stock in Your Portfolio for Now

by Zacks Equity Research

BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.

Zacks Equity Research

TMCI Stock May Gain From the Limited Release of the Percuplasty System

by Zacks Equity Research

Treace Medical announces the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, targeting the in-demand bunion surgery market.

Zacks Equity Research

Cencora Stock May Gain Following the Strategic Acquisition of RCA

by Zacks Equity Research

COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.

Zacks Equity Research

Reasons to Add Cardinal Health Stock to Your Portfolio Now

by Zacks Equity Research

CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY)

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Here's Why You Should Add MMSI Stock to Your Portfolio Now

by Zacks Equity Research

Merit Medical's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device

by Zacks Equity Research

INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.

Zacks Equity Research

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

by Zacks Equity Research

RVTY's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings Stock in Your Portfolio

by Zacks Equity Research

ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.

Moumi Mondal headshot

5 Beaten-Down MedTech Stocks Set to Rebound in 2025

by Moumi Mondal

Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

Zacks Equity Research

HealthEquity Gains 46.8% in a Year: What's Driving the Stock?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

by Zacks Equity Research

ECL continues to gain from its strong segmental performance and improved operating margin.